Syndicated Research Studies

The global infectious disease molecular diagnostics market was valued at USD 16.24 billion in 2024 and is projected to reach USD 20.15 billion by 2030, expanding at a CAGR of 3.4% from 2025 to 2030. This growth is primarily driven by the rising global prevalence of infectious diseases. According to the World Health Organization, as of January 22, 2025, more than 5,000 chikungunya virus disease (CHIKVD) cases and two deaths were reported across four countries worldwide. In 2024, a total of 620,000 cases and 213 deaths were documented, mostly in the Americas, with Brazil, Paraguay, and Argentina experiencing the highest infection rates. In Asia, India and Pakistan reported significant numbers of cases, while Senegal remained the only affected country in Africa. Europe recorded one locally transmitted case in France and 118 cases in La Réunion. Beyond chikungunya, persistent public health threats such as HIV/AIDS, tuberculosis, hepatitis, and respiratory infections continue to ele...

Infectious Disease Molecular Diagnostics Industry Overview The global infectious disease molecular diagnostics market size was valued at USD 32.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.0% from 2020 to 2028. The growth can be attributed to the growing use of molecular diagnostics in infection detection, the rising geriatric population, and the increasing demand for point-of-care molecular diagnostics. The outbreak of COVID-19 is anticipated to act as a key driver. Gather more insights about the market drivers, restrains and growth of the Global Infectious Disease Molecular Diagnostics Market The global geriatric population is increasing. Over 727.0 million people globally were categorized in the age group 65 and above. The geriatric population is more susceptible to COVID-19 owing to multimorbidity, decreased immune function, and physiological changes associated with aging. According to CDC in 2021, 80% of COVID-19 related deaths wer...